{
    "pmcid": "8514607",
    "qa_pairs": {
        "How do nanobodies enhance their binding affinity and neutralization potency against SARS-CoV-2?": [
            "By engineering them into multivalent or biparatopic formats.",
            "By increasing their molecular weight through glycosylation.",
            "By shortening their CDR3 regions to improve binding kinetics.",
            "By incorporating additional disulfide bonds for structural rigidity."
        ],
        "What are nanobodies, and what is their origin?": [
            "Nanobodies, also known as VHHs, are single-domain antibodies derived from camelid heavy-chain antibodies.",
            "Nanobodies are small peptides derived from human antibodies.",
            "Nanobodies are synthetic molecules designed to mimic antibody functions.",
            "Nanobodies are protein fragments derived from bacterial cell walls."
        ],
        "What challenge do SARS-CoV-2 variants like E484K and N501Y pose, and how can nanobodies address this?": [
            "Variants pose mutational escape challenges, and nanobodies can target conserved epitopes less prone to mutation.",
            "Variants increase viral replication rates, and nanobodies can inhibit viral polymerase activity.",
            "Variants enhance viral shedding, and nanobodies can reduce viral load in bodily fluids.",
            "Variants alter viral entry mechanisms, and nanobodies can block alternative entry pathways."
        ],
        "What is a potential advantage of using nanobodies for pulmonary delivery in COVID-19 treatment?": [
            "Their stability allows for administration via inhalation, targeting respiratory infections.",
            "Their large size enables prolonged retention in the respiratory tract.",
            "Their hydrophobic nature enhances absorption through the pulmonary epithelium.",
            "Their rapid degradation ensures minimal systemic exposure."
        ],
        "What structural feature of nanobodies contributes to their antigen recognition capabilities?": [
            "They have longer CDR3 regions compared to human VH domains.",
            "They have shorter CDR1 regions compared to human VH domains.",
            "They have additional disulfide bonds compared to human VH domains.",
            "They have a unique glycosylation pattern compared to human VH domains."
        ]
    }
}